• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

News & Events

  • Print
  • Share
  • E-mail

Review of the ReGen Menaflex

Preliminary findings and recommendations regarding FDA's review and clearance of ReGen Biologics Inc.'s submission to market a device for use in treating injuries to the meniscus (knee cartilage).

Transcript for FDA's Media Briefing on the FDA's Review of the ReGen Menaflex

Accessibility Information

Persons with disabilities having problems accessing the Attachment may contact Tina Gilliam, 301-796-5217 for assistance.